4.6 Review

Regulation of RAD51 at the Transcriptional and Functional Levels: What Prospects for Cancer Therapy?

Journal

CANCERS
Volume 13, Issue 12, Pages -

Publisher

MDPI
DOI: 10.3390/cancers13122930

Keywords

RAD51; homologous recombination; DNA repair; genomic instability; DNA break; cancer therapy

Categories

Funding

  1. SIRIC Montpellier Cancer Grant [INCa-DGOSInserm_12553]

Ask authors/readers for more resources

RAD51 is an essential gene for cell survival, playing a crucial role in DNA repair and elevated expression in cancers. Targeting RAD51 expression or function could have therapeutic value. It functions as a critical effector of HR, forming homopolymetric filaments at DNA breaks. In normal cells, RAD51 expression is low and tightly regulated, but elevated in many cancers, associated with sensitivity to genotoxic treatment.
Simple Summary RAD51 is an essential gene for cell survival. Its function is central to DNA repair and it protects cells from life-threatening damage to the genome. Interestingly, RAD51 is expressed at high levels in a large proportion of cancers, and elevated RAD51 expression is associated with a bad outcome and reduced response to treatment. Hence, reducing RAD51 expression and/or interfering with its function could be of great therapeutic value. We review here the multiple levels of regulation of RAD51 expression and function and explore potential therapeutic leads. The RAD51 recombinase is a critical effector of Homologous Recombination (HR), which is an essential DNA repair mechanism for double-strand breaks. The RAD51 protein is recruited onto the DNA break by BRCA2 and forms homopolymeric filaments that invade the homologous chromatid and use it as a template for repair. RAD51 filaments are detectable by immunofluorescence as distinct foci in the cell nucleus, and their presence is a read out of HR proficiency. RAD51 is an essential gene, protecting cells from genetic instability. Its expression is low and tightly regulated in normal cells and, contrastingly, elevated in a large fraction of cancers, where its level of expression and activity have been linked with sensitivity to genotoxic treatment. In particular, BRCA-deficient tumors show reduced or obliterated RAD51 foci formation and increased sensitivity to platinum salt or PARP inhibitors. However, resistance to treatment sets in rapidly and is frequently based on a complete or partial restoration of RAD51 foci formation. Consequently, RAD51 could be a highly valuable therapeutic target. Here, we review the multiple levels of regulation that impact the transcription of the RAD51 gene, as well as the post-translational modifications that determine its expression level, recruitment on DNA damage sites and the efficient formation of homofilaments. Some of these regulation levels may be targeted and their impact on cancer cell survival discussed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available